A randomised controlled trial with a diphtheria–tetanus–acellular pertussis (dTpa) vaccine in adults

M Van der Wielen, P Van Damme, E Joossens… - Vaccine, 2000 - Elsevier
The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …

Immunogenicity of a combined diphtheria–tetanus–acellular pertussis vaccine in adults

P Van Damme, M Burgess - Vaccine, 2004 - Elsevier
Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults

FM Turnbull, TC Heath, BB Jalaludin, MA Burgess… - Vaccine, 2000 - Elsevier
A single blinded randomized controlled trial to compare the reactogenicity and
immunogenicity of adult formulated dTpa and monovalent pa vaccines with a licensed Td …

Immunogenicity and reactogenicity of a single dose of a diphtheria–tetanus–acellular pertussis component vaccine (DTaP) compared to a diphtheria–tetanus toxoid …

I Bartels, J Jüngert, S Lugauer, K Stehr, U Heininger - Vaccine, 2001 - Elsevier
We compared immunogenicity and reactogenicity of a single dose of DTaP vaccine
(containing tetanus and diphtheria toxoids and four acellular pertussis antigens) with …

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) …

B Thierry-Carstensen, K Jordan, HH Uhlving, T Dalby… - Vaccine, 2012 - Elsevier
BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …

Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old …

P Kosuwon, B Warachit, Y Hutagalung, T Borkird… - Vaccine, 2003 - Elsevier
A trial to compare the reactogenicity and immunogenicity of a reduced antigen content
diphtheria–tetanus–acellular pertussis (dTpa) vaccine with diphtheria–tetanus–whole-cell …

Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccines as a booster in 4–7-year-old children primed with …

R Dagan, K Igbaria, L Piglansky, F Van Brusteghem… - Vaccine, 1999 - Elsevier
Background. The recent introduction of acellular pertussis vaccines (Pa) offers the possibility
of booster doses in older children and adults. This can be conveniently accomplished by …

Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults

C Sirivichayakul, P Chanthavanich… - Human vaccines & …, 2017 - Taylor & Francis
ABSTRACT Background: An acellular Pertussis (aP) vaccine containing recombinant
genetically detoxified Pertussis Toxin (PTgen), Filamentous Hemagglutinin (FHA) and …

Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV)

M Knuf, V Vetter, F Celzo, G Ramakrishnan… - Human …, 2010 - Taylor & Francis
Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …

Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learned

C Capiau, J Poolman, B Hoet, H Bogaerts, F Andre - Vaccine, 2003 - Elsevier
The widespread use of whole-cell pertussis vaccines in the second half of the 20th century
have reduced the incidence of the disease significantly. However, in some countries …